Pathological role of angiostatin in heart failure: An endogenous inhibitor of mesenchymal stem-cell activation

Heart

Volumn 95, Issue 4, 2009, Pages 283-289

  Yamahara, K ^a,b   Min, K D ^a   Tomoike, H ^a   Kangawa, K ^a   Kitamura, S ^a   Nagaya, N ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b National Cardiovascular Center ^*  (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; BRAIN NATRIURETIC PEPTIDE; GELATINASE B; HUMORAL ANTIBODY; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CARDIOMYOPATHY; CELL ACTIVATION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE COURSE; ECHOCARDIOGRAPHY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LEWIS RAT; MALE; MESENCHYMAL STEM CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN MICROARRAY; RAT; WESTERN BLOTTING;

ANGIOSTATINS; ANIMALS; APOPTOSIS; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEART FAILURE; HUMANS; INTERLEUKIN-6; MALE; MATRIX METALLOPROTEINASE 9; MESENCHYMAL STEM CELLS; PROTEIN ARRAY ANALYSIS; RATS; RATS, INBRED LEW; TUMOR NECROSIS FACTOR-ALPHA;

EID: 62149088174     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2008.152223     Document Type: Article

References (28)

1. Yamahara K, Nagaya N. Mesenchymal stem cells for the treatment of heart disease. Regen Med 2007;2:107-9.
2. Bittira B, Shum-Tim D, Al-Khaldi A, et al. Mobilization and homing of bone marrow stromal cells in myocardial infarction. Eur J Cardiothorac Surg 2003;24:393-8.
3. Miyahara Y, Nagaya N, Kataoka M, et al. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat Med 2006;12:459-65.
4. Jaganathan BG, Ruester B, Dressel L, et al. Rho inhibition induces migration of mesenchymal stromal cells. Stem Cells 2007;25:1966-74.
5. Nagaya N, Kangawa K, Itoh T, et al. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation 2005;112:1128-35.
6. Curci JA, Petrinec D, Liao S, et al. Pharmacologic suppression of experimental abdominal aortic aneurysms: acomparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg 1998;28:1082-93.
7. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
8. Walter JJ, Sane DC. Angiostatin binds to smooth muscle cells in the coronary artery and inhibits smooth muscle cell proliferation and migration In vitro. Arterioscler Thrombosis Vase Biol 1999;19:2041-8.
9. Chi SL, Pizzo SV. Angiostatin is directly cytotoxic to tumor cells at low extracellular pH: a mechanism dependent on cell surface-associated ATP synthase. Cancer Res 2006;66:875-82.
10. Lucas R, Holmgren L, Garcia I, et al. Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 1998;92:4730-41.
11. Claesson-Welsh L, Welsh M, Ito N, et al. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrinbinding motif RGD. Proc Natl Acad Sci U S A 1998;95:5579-83.
12. Hanford HA, Wong CA, Kassan H, et al. Angiostatin(4.5)- mediated apoptosis of vascular endothelial cells. Cancer Res 2003;63:4275-80.
13. Ji WR, Castellino FJ, Chang Y, et al. Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. FASEB J 1998;12:1731-8.
14. Perri SR, Annabi B, Galipeau J. Angiostatin inhibits monocyte/macrophage migration via disruption of actin cytoskeleton. FASEB J 2007;21:3928-36.
15. Matsunaga T, Weihrauch DW, Moniz MC, et al. Angiostatin inhibits coronary angiogenesis during impaired production of nitric oxide. Circulation 2002;105:2185-91.
16. Kobayashi T, Watanabe H, Yanagawa T, et al. Motility and growth of human bonemarrow mesenchymal stem cells during ex vivo expansion in autologous serum. J Bone Joint Surg Br 2005;87:1426-33.
17. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:23B-41.
18. MacGowan GA, Mann DL, Kormos RL, et al. Circulating interleukin-6 in severe heart failure. Am J Cardiol 1997;79:1128- 31.
19. Falcone DJ, Khan KM, Layne T, et al. Macrophage formation of angiostatin during inflammation. A byproduct of the activation of plasminogen. J Biol Chem 1998;273:31480-5.
20. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060-7.
21. Askari AT, Unzek S, Popovic ZB, et al. Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy. Lancet 2003;362:697-703.
22. Saito T, Kuang JQ, Bittira B, et al. Xenotransplant cardiac chimera: immune tolerance of adult stem cells. Ann Thorac Surg 2002;74:19-24.
23. Cornelius LA, Nehring LC, Harding E, et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 1998;161:6845-52.
24. Thomas CV, Coker ML, Zellner JL, et al. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 1998;97:1708-15.
25. Tziakas DN, Chalikias GK, Papaioakeim M, et al. Comparison of levels of matrix metalloproteinase-2 and -3 in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy. Am J Cardiol 2005;96:1449-51.
26. Manning MW, Cassis LA, Daugherty A. Differential effects of doxycycline, a broadspectrum matrix metalloproteinase inhibitor, on angiotensin ll-induced atherosclerosis and abdominal aortic aneurysms. Arterioscler Thrombosis Vasc Biol 2003;23:483-8.
27. Kodama M, Hanawa H, Saeki M, et al. Rat dilated cardiomyopathy after autoimmune giant cell myocarditis. Circ Res 1994;75:278-84.
28. Siveski-lliskovic N, Hill M, Chow DA, et al. Probucol protects against adriamycin cardiomyopathy without interfering with its antitumor effect. Circulation 1995;91:10-15.